Cite
HARVARD Citation
Adenis, A. et al. (2016). Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC cancer. 16 (1), pp. 1-8. [Online].